Aphton, Celltrion deal

APHT's Igeneon subsidiary (Vienna, Austria) and Celltrion signed a letter of intent to amend a 2005 deal in which Igeneon granted Celltrion commercialization rights to IGN311 in certain Asian countries, including Japan (see BioCentury, Aug. 1, 2005). The amendment would give Celltrion commercialization rights in Europe and a license to commercialize Igeneon's next-generation antibody, IGN312, in the same territories. Both antibodies target the Lewis Y antigen. IGN311 is in Phase Ib testing to treat Lewis Y positive tumors, while IGN312 is in preclinical development. ...